NCT01162980

The Angiotensin Converting Enzyme (ACE) Inhibitor SwitchBack Study

The ACEi SwitchBack Study

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 100 (estimated)
• Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

ACE inhibitors have been studied extensively in the treatment of heart failure and have been shown to be beneficial in all its stages. Studies with the use of angiotensin receptor blockers (ARBs) in chronic heart failure have not shown equivalent results. Many patients are on an ARB for a variety of reasons. Some of these may have had cough as a symptom of heart failure and not due to medication side effect. According to guidelines, angiotensin converting enzyme inhibitors (ACEi) are still first-line therapy in the treatment of heart failure. As ACEi have been extensively studied showing improvement in morbidity and mortality all patients should be on this treatment unless absolutely contraindicated.

Conditions

• Heart Failure

Timeline

• Start date: 2010-07-01
• Primary completion: 2012-01-01
• Completion: 2012-07-01
• First posted: 2010-07-15
• Last updated: 2010-07-15

Locations

1 site across 1 country: Canada